Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Casper Sleep, Inc. Common Stock – CSPRBROOKLYN, N.Y., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Eastern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers of Casper Sleep, Inc. common stock (
NYSECSPR):
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMABNEW YORK, July 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers of stock of Y-mAbs Therapeutics, Inc. (
NASDAQYMAB):
Pomerantz LLP Announces Pendency of Class Action Involving Purchasers of Franklin Wireless Corp. SecuritiesSAN DIEGO, May 20, 2024 (GLOBE NEWSWIRE) -- The following statement is being issued by Pomerantz LLP regarding the Franklin Wireless Corp. Securities Litigation.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Integra Lifesciences Holdings Corp - IARTNEW YORK, March 27, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating whether the Board of Directors of Integra Lifesciences Holdings Corp (
NASDAQIART) (“Integra”) potentially breached their fiduciary duties to shareholders. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sotera Health Company - SHCNEW YORK, March 27, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating whether the Board of Directors of Sotera Health Company (
NASDAQSHC) (“Sotera”) potentially breached their fiduciary duties to shareholders. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – FATENEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of Fate Therapeutics, Inc. (“Fate” or the “Company”) (
NASDAQFATE). The class action, filed in the United States District Court for the Southern District of California, and docketed under 23-cv-111-WQH-NLS, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fate securities between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
